MedImmune Takeover After this long run of failed late-stage clinical trials, in April of 2007 AstraZeneca bought vaccine maker MedImmune, paying $15.2 billion primarily for its drug development pipeline. Analysts have criticized this take-over, claiming that AstraZeneca paid too much[8]. ...
To do this, we work with our two biotech units – Innovative Medicines and Early Development (IMED) and MedImmune – and the Global Portfolio and Product Strategy (GPPS) organisation to understand where there is unmet medical need, to shape our therapy area strategies from early development ...
In October 2013, AstraZeneca Plc completed its acquisition of Amplimmune. In October 2013, AstraZeneca PLC announced that MedImmune acquired Spirogen. General information Organization name AstraZeneca (USA) Organization status Operating organization Site http://www.astrazeneca-us.com/home/ Awards...
The important things you want to know before Go-Live Invoicing methods via Coupa From March 31st onwards all new AstraZeneca UK Limited and MedImmune Limited Purchase Orders will be sent using Coupa. Suppliers are expected to send all related invoices back to AstraZeneca through the Coupa ...
In another early-stage bet, AstraZeneca’s MedImmune unit acquired the biotech AlphaCore Pharma. The deal comes as AstraZeneca ($AZN) reboots a floundering R&D effort and adds a recombinant LCAT enzyme therapy from AlphaCore that could combat cardiovascular disease. MedImmune, the biologics divis...
Parrish et al., “Preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders”, CAPLUS 138:304153, 2003. Primary Examiner: JACKSON, SHAWQUIA Attorney, Agent or Firm: ASTRAZENECA MEDIMMUNE (Gaithersburg, MARYLAND...